Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764489 | 0.93 | MEN1 (0.41) | RXFP1MEN1KMT2AMAPTTP53 | |
| SCHEMBL20764488 | 0.93 | MEN1 (0.41) | RXFP1MEN1KMT2AMAPTTP53 | |
| SCHEMBL22100102 | 0.89 | MAPT (0.34) | RXFP1KMT2AMAPTTP53RAB9A | |
| SCHEMBL22099982 | 0.89 | NR1H4 (0.44) | RXFP1MEN1KMT2AMAPTTP53 | |
| SCHEMBL22099918 | 0.89 | NAMPT (0.37) | — | |
| SCHEMBL22099914 | 0.89 | RORC (0.38) | RXFP1MEN1KMT2AMAPTTP53 | |
| SCHEMBL20764589 | 0.89 | MMP2 (0.35) | RXFP1MEN1KMT2A | |
| SCHEMBL20764587 | 0.89 | MMP2 (0.35) | RXFP1MEN1KMT2A | |
| SCHEMBL22099929 | 0.88 | P4HTM (0.36) | RXFP1MAPTTP53RAB9AKDM4E | |
| SCHEMBL20764527 | 0.87 | NR1H4 (0.38) | KMT2AMAPTPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | RXFP1 896/4885MEN1 2023/4885KMT2A 2115/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | RXFP1 1126/4885MEN1 2097/4885KMT2A 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.